ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy

Luo, Yong; Liu, Xiaopeng; Lin, Jingbo*; Zhong, Weide*; Chen, Qingbiao*广州医学院; 南方医科大学; 1
Mathematical Biosciences and Engineering2022DOI: 10.3934/mbe.2022528
9阅读
引用收藏
分享

摘要

The aim of this study is to construct an inflammatory response-related genes (IRRGs) signature to monitor biochemical recurrence (BCR) and treatment effects in prostate cancer patients (PCa). A gene signature for inflammatory responses was constructed on the basis of the data from the Cancer Genome Atlas (TCGA) database, and validated in external datasets. It was analyzed using receiver operating characteristic curve, BCR-free survival, Cox regression, and nomogram. Distribution analysis and external model comparison were utilized. Then, enrichment analysis, tumor mutation burden, tumor immune microenvironment, and immune cell infiltration signatures were investigated. The role of the signature in immunotherapy was evaluated. The expression patterns of core genes were verified by RNA sequencing. We identified an IRRGs signature in the TCGA-PRAD cohort and verified it well in two other independent external datasets. The signature was a robust and independent prognostic index for predicting the BCR of PCa. The high-risk group of our signature predicted a shortened BCR time and an aggressive disease progression. A nomogram was constructed to predict BCR-free time in clinical practices. Neutrophils and CD8+ T cells were in higher abundance among the low-risk individuals. Immune functions varied significantly between the two groups and immune checkpoint therapy worked better for the low-risk patients. The expression of four IRRGs showed significant differences between PCa and surrounding benign tissues, and were validated in BPH-1 and DU145 cell lines by RNA sequencing. Our signature served as a reliable and promising biomarker for predicting the prognosis and evaluating the efficacy of immunotherapy, facilitating a better outcome for PCa patients.

学科与关键词

关键词
prostate cancerinflammatory responsebiochemical recurrenceimmune cellimmune checkpoint therapy
相关
加载中…
  • An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer
    Zhang, Guian; Luo, Yong*International Journal of General Medicine, 2021, 14: 9031-9049.被引 1
  • Inflammation-related signature for prognostic prediction, tumor immune, genomic heterogeneity, and drug choices in prostate cancer: Integrated analysis of bulk and single-cell RNA-sequencing
    Zhu, Weian; Huang, Jiongduan; Wu, Jianjie; Wu, Chenglun; Ye, Fengxi; Li, Xiang*; Lai, Wenjie*Heliyon, 2023, 9(11): e21174.
  • Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer
    Zhang, Guian; Luo, Yong; Dong, Weimin; Zhong, Weide*Computational and Mathematical Methods in Medicine, 2022, 2022: 8233840.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Mathematical Biosciences and Engineering
发表日期
2022
卷期
第 19 卷, 第 11 期
页码
11345-11366
DOI
10.3934/mbe.2022528
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
Guangdong Medical Science and Technology Research Fund Project [B2022332, B2020127]; Foshan Science and Technology Innovation Project [2020001005794]; National Natural Science Foundation of China [82072813, 81571427]; Guangzhou Municipal Science and Technology Project [201803040001]

作者

  • L

    Luo, Yong (第一作者)

    2 · southern med univ

  • L

    Liu, Xiaopeng

    2 · southern med univ

查看全部 5 位作者收起作者
  • L

    Lin, Jingbo (通讯)

    2 · southern med univ

  • Z

    Zhong, Weide (通讯)

    2 · southern med univ · 1 · guangzhou med univ

  • C

    Chen, Qingbiao (通讯)

    2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417